PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. reduced its stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 56.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,701 shares of the company's stock after selling 200,136 shares during the period. Assenagon Asset Management S.A. owned 0.30% of PMV Pharmaceuticals worth $232,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Cubist Systematic Strategies LLC boosted its holdings in shares of PMV Pharmaceuticals by 570.8% in the second quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company's stock valued at $113,000 after purchasing an additional 59,452 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of PMV Pharmaceuticals in the 2nd quarter worth $101,000. BML Capital Management LLC lifted its holdings in shares of PMV Pharmaceuticals by 29.0% in the 3rd quarter. BML Capital Management LLC now owns 1,688,772 shares of the company's stock worth $2,516,000 after buying an additional 379,375 shares during the period. Sio Capital Management LLC grew its position in shares of PMV Pharmaceuticals by 18.7% during the 3rd quarter. Sio Capital Management LLC now owns 3,214,239 shares of the company's stock worth $4,789,000 after buying an additional 505,831 shares in the last quarter. Finally, PFM Health Sciences LP increased its stake in shares of PMV Pharmaceuticals by 57.7% during the third quarter. PFM Health Sciences LP now owns 2,011,040 shares of the company's stock valued at $2,996,000 after buying an additional 735,578 shares during the period. 90.20% of the stock is owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Trading Down 1.4 %

Shares of PMVP traded down $0.02 during trading hours on Friday, hitting $1.37. The company had a trading volume of 42,172 shares, compared to its average volume of 160,027. PMV Pharmaceuticals, Inc. has a one year low of $1.32 and a one year high of $2.26. The company's fifty day moving average price is $1.52 and its two-hundred day moving average price is $1.55.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). As a group, equities research analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Oppenheimer raised shares of PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 target price on the stock in a research report on Friday, November 8th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $5.50.

PMV Pharmaceuticals Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.